Moderna lifts annual revenue forecast

MODERNA lifted its full-year revenue forecast on Friday after strong international Covid-19 vaccine demand and payments from partnerships helped the biotech swing to profit in the third quarter, sending its shares up over 10 percent. The rally builds on a blockbuster year for Moderna, whose stock has skyrocketed more than eightfold, largely fueled by encouraging late-stage data from its personalized cancer vaccine candidate developed with Merck. The upbeat results serve as a “cherry on top